Aviva’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Aviva’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-19,500	Closed	-$3.04M	–	833
2014 Q4	$3.04M	Buy	+19,500	New	+$3.6M	0.02%	642
2014 Q3	–	Sell	-8,824	Closed	-$2.09M	–	848
2014 Q2	$2.09M	Buy	+8,824	New	+$2.33M	0.02%	716

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Aviva's ICPT Position: Q1 2015 in Review

Aviva sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2015, closing a stake of 19,500 shares — an estimated $3.04M sold.

Aviva first reported a position in ICPT in Q2 2014 and held it in 2 quarters. The position peaked at $3.04M in Q4 2014. 200 funds tracked by Wall St. Rank hold ICPT as of Q1 2015.

Aviva reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
Aviva sold 19,500 Intercept Pharmaceuticals, Inc. shares in Q1 2015, an estimated $3.04M.
Aviva first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2014 and held it in 2 quarters.
Aviva's Intercept Pharmaceuticals, Inc. position peaked at $3.04M in Q4 2014.
200 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2015.

Based on Aviva's 13F filing for Q1 2015, filed 14 May 2015.